{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"description":"Disease stability was assessed by evaluating the proportion of participants who are progression free (and alive) at 6 months.\n\nProgression was defined as any one or more of the following:\n\nAn increase of 25% from lowest confirmed response:\n\n* Serum M-component (absolute increase \\>=1.0 g/dL)\n* Urine M-component (absolute increase \\>=200 mg/24 hours)\n\nAn increase of 50% above the lowest remission value in bone marrow plasmacytosis (absolute increase 25% bone marrow plasma cells)\n\nDevelopment of new bone lesions or soft tissue plasmacytomas.","groups":[{"id":"OG000","title":"Anakinra With/Without Dexamethasone"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"at 6 months","title":"Number of Patients Who Are Progression-free and Alive at 6 Months","type":"SECONDARY","unitOfMeasure":"participants"}